






























bLung Cancer 89 (2015) 320–328
Contents lists available at ScienceDirect
Lung Cancer
journa l homepage: www.e lsev ier .com/ locate / lungcan
esticular orphan receptor 4 (TR4) is a marker for metastasis and poor
rognosis in non-small cell lung cancer that drives the EMT phenotype
iyi Zhanga,1, Jianzhi Zhanga,1, Yuanyuan Maa,1, Jinfeng Chena, Bin Dongb, Wei Zhaoc,
ing Wanga, Qinfeng Zhenga, Fang Fanga, Yue Yanga,∗
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery II, Beijing, People’s Republic of China
Central Laboratory, Peking University Cancer Hospital & Institute, Beijing 100142, People’s Republic of China
Department of Cell Biology, Peking University Cancer Hospital & Institute, Beijing 100142, People’s Republic of China
r t i c l e i n f o
rticle history:
eceived 11 December 2014
eceived in revised form 30 May 2015
ccepted 11 June 2015
eywords:






a b s t r a c t
Objectives:Aberrantexpressionof testicularorphanreceptor4 (TR4)hasbeenshownto regulatebiological
processes near solid tumors. However, the role of TR4 in non-small cell lung cancer (NSCLC) patient
prognosis and the development of NSCLC cancer cells are unclear.
Methods: Immunohistochemical analysis was used to evaluate the correlation between TR4 expression
and clinicopathological characteristics in 291 cases of NSCLC specimens. A knockdown and overex-
pression of TR4 was performed to assess the role of TR4. Transwell and colony formation assays were
completed to investigate the metastatic and proliferative abilities. Quantitative real-time PCR, Western
blotting and immunoﬂuorescence staining were carried out to analyze the epithelial-to-mesenchymal
transition (EMT) phenotype.
Results: Immunohistochemical evaluation of clinical samples revealed thatmost of the lung cancer tissues
were strongly positive for TR4, whereas the tissues that stained weakly positive or negative for TR4
expression were shown in the paired normal tissues. Moreover, higher levels of TR4 expression were
signiﬁcantly associated with higher lymph node metastases, TNM stages, tumor thrombus in vena and
poor prognosis. We observed that downregulation and up-regulation of TR4 with stable cell transfection
signiﬁcantly inﬂuence the proliferation, invasive and metastatic abilities of NSCLC lines. In addition,
aberrant TR4 expression could modulate the expression levels of several EMT related markers.
Conclusions: Collectively, our results show TR4 expression in NSCLC samples is signiﬁcantly associated
with poor clinicopathological features, and TR4 plays an important role in the metastatic capacity of
NSCLC cells by EMT regulation.
rs. Pu© 2015 The Autho
. Introduction
Lung cancer is the leading cause of cancer-related deathsworld-
ide and ranks among the most commonly occurring and fatal
alignancies [1]. The primary tumor, lymph node (LN) and the
etastasis (TNM) staging systemremain themost important deter-
inant of outcome, and poor survival in NSCLC is partly due
o development of metastasis [2]. Non-small cell lung cancer
NSCLC) accounts for approximately 80% of cases. Of the patients
ho exhibit NSCLC, approximately 30% to 50% will present with
etastatic disease [3].
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Testicular orphan receptor 4 (TR4; nuclear receptor subfamily
2, group C, member 2) belongs to the nuclear receptor super family
and encodes a 67-kDa protein [4–6]. TR4 is a transcriptional factor
that regulates many signal pathways in normal spermatogenesis,
cerebellum development, glucose metabolism and insulin resis-
tance [7–11]. TR4 heterodimerizes with testicular orphan receptor
2 (TR2, nuclear receptor subfamily 2, group C, member 1) and the
complex binds to direct repeatswith one nucleotide of the DR1 ele-
ment that inhibits target gene transcription [12–15]. This nuclear
protein, TR4, could suppress various factors, such as ER, andro-
gen receptor (AR) and the steroid 21-hydroxylase [16–18]. Several
studies have shown that TR4 is widely expressed in human tissues,
including testis, prostate, ovary, brain and lung [4,5,19,20]. In addi-
tion, TR4 has been demonstrated to activate target gene expression
in liver carcinoma HepG2 cells [21]. Recently, Yang et al. found
that TR4 was located in prostate tumor cells and suggested that
TR4 may function through Oct4 and IL1Ra to modulate prostate
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ancer progression and chemo-resistance [22]. Furthermore, Du
t al. indicated thatTR4couldpromotepituitary corticotroph tumor
rogression [16].
Epithelial-to-mesenchymal transition (EMT) is a process dur-
ng which epithelial cells acquire more migratory and invasive
roperties [23,24]. Several transcriptional factors are known to be
nvolved in the regulation of EMT, including Snail, Slug and Twist,
hich simultaneously induce the expression of genes required for
he mesenchymal phenotype, such as Vimentin, and repress the
xpression of genes required formaintaining epithelial phenotype,
uch as E-cadherin [25,26].
NSCLC are particularly aggressive tumors, with high invasive
roperties andmetastaticpotential. About40%stage I and60%stage
I NSCLC patients are dying of distant metastases within 5 years
fter curative tumor resection [27]. Therefore, we aimed to explore
hecrucial roleofTR4 in291casesof I-IIIANSCLCwithorwithout LN
etastasis. We demonstrated that TR4 expression was associated
ith theoccurrenceof LNmetastasis and thepostoperative survival
eriod for NSCLC patients. TR4 induced cellmetastatic and invasive
apacities in lungcancer cells, at least inpart, through theactivation
f the EMT signaling pathway.
. Materials and methods
.1. Tissue specimens and immunohistochemistry (IHC)
NSCLC tumor specimens were collected with informed con-
ent from 291 patients who underwent surgical resection at
he Department of Thoracic Surgery of Beijing Cancer Hospital
etween December 1995 and December 2009. Written consent
tatements were obtained from all patients before operation.
ormalin-ﬁxed and parafﬁn-embedded primary lung cancer sam-
les were acquired from the Department of Pathology, Peking
niversity, under approval from the Ethical Committee. The clini-
al and pathological features of all cases were summarized in Table
1.
The primary antibodies used in this study included anti-TR4
ntibody (rabbit monoclonal 1:200 dilution; Abcam, UK), anti-
imentin antibody (rabbit monoclonal 1:500 dilution; Abcam,
K), anti-E-cadherin antibody (rabbit monoclonal 1:500 dilu-
ion; Abcam, UK). Sections (4m) were routinely processed and
tained with rabbit monoclonal antibodies followed by incubation
ith HRP-conjugated goat anti-rabbit secondary antibody (Sigma-
ldrich, Poole, Dorset, UK). For determination of immunoreactivity
or the previouslymentionedmarkers, cytosolic staining of yellow-
sh or brownish granuleswas graded as follows: (A) for background
taining; (B) for negative staining; (C) formoderate staining and (D)
or strong staining. In addition, positive staining areas in the entire
issue sectionwere graded as follows: 0, for <5%; 1, for 5–25%; 2, for
6–50% and 3, >50%. When combining these two parameters, 0–1
nd>1were considerednegative andpositive staining, respectively
Fig. 1A). In the case of TR4 and Vimentin, samples were scored as
ositivewhen greater than 5% of tumor cells showedpositive stain-
ng in the nucleus or cytoplasm. In the case of E-cadherin, tumors
ere scored as 0 to 3 according to different staining. Tumors scored
s0or1were considered “negative”, and those scoredas2or3were
lassiﬁed as “positive”.
.2. Cell linesLung cancer cell lines (A549, PC-9, H1299, GLC82) were main-
ained under standard cell culture conditions in RPMI-1640 media
upplemented with 10% fetal bovine serum (FBS; Gibco, Australia),
00U/mlpenicillin and100g/ml streptomycin (Invitrogen,Grand
sland,NY) in ahumidiﬁed atmosphere of 5%CO2 at 37 ◦C incubator.r 89 (2015) 320–328 321
2.3. Plasmid construction and cell transfection
pGPH1/GFP/Neo-shTR4 was constructed (Suzhou GenePharma
Co., China) and transfected into two lung cancer cell lines, A549
and PC-9. As a negative control, control vector shNC (Suzhou
GenePharma Co., China) was transfected in the A549 and PC-9
cells. The ORF of human TR4 gene was ampliﬁed with fol-
lowing primers (forward primer 5′-CTCTCGGCCGGAATCTCCA-3′
and reverse primer 5′-GGCAGGTGTGTGGTTTGC-3′) from A549
cells, and subcloned into the XhoI/BamHI sites of GV144 vector
(GenechemCo., China), and transfected intoH1299 andGLC82 cells
by lipofectamine 2000 (Invitrogen) following the manufacturer’s
protocol. CON107 (Genechem Co., China) was used as control. Sta-
ble single colony cells of TR4 knockdown and overexpress were
screened by 500g/ml of G418 (Sigma-Aldrich) for 2 weeks and
then the cells were expanded and harvested for Quantitative real-
time PCR (QPCR) or Western blot analysis (Fig. 2).
2.4. Boyden chamber cell migration and cell invasion assay
BD BioCoatMatrigel Invasion Chambers, with 8.0mPETmem-
brane 24-well cell culture inserts packaged ready-to-use in BD
Falcon Companion Plates and Growth Factor Reduced BD Matrigel
Matrix, a solubilized basement membrane (BD Biosciences, San
Jose, CA, USA) were used in Matrigel invasion assays. Assay was
performed according to the manufacturer’s protocol. A total of
1.0×105 cells perwell in serum-freeRPMIwereplaced in theupper
chamber. RPMI plus 10% FBS was placed in the lower chamber
as a source of chemo attractant. Transfected A549 and PC-9 cells
were allowed to migrate through pores for 24h at 37 ◦C. The total
numbers of cells migrated or invaded through the matrigel were
counted after crystal violet staining and photographed.
2.5. Colony formation
Approximately 1000 transfected A549 and PC-9 cells were
replated into 10 cm dishes. Two weeks later, visible colonies were
ﬁxed and stainedwith crystal violet, and the colony formation ratio
was calculated with the following formula: (visible colony num-
bers/original number of cells)×100%. Data are presented as the
mean± SD and experimentswere performed in triplicate. * P<0.05.
2.6. Reverse transcription and QPCR
RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA)
followed bymanufacturer’s protocol. Twomicrograms of total RNA
was added and reverse transcribedwithMoloneymurine leukemia
virus (MMLV, Invitrogen). PCR reactions were performed by The
LightCycler®480 SYBR Green I Master on Light-Cycler®480 Real-
Time PCR System (Roche, USA). Sequences of all primers are listed
in Table A2. GADPH was used as a loading control. Cycling con-
ditions were as follows: 5min at 95 ◦C, followed by 45 cycles each
consisting of 10 s at 95 ◦C, 20 s at 60 ◦C and 30 s at 72 ◦C. The relative
amount of genes was normalized to GADPH. Data was calculated
basedon2−Ct whereCt =Ct (Target)—Ct (Reference). Fold change
was calculated by the 2−Ct method.
2.7. Western blot analysis
Protein was extracted from cells using RIPA buffer con-
taining complete protease inhibitor cocktail (Roche, Mannheim,
Germany). Proteins were separated on SDS-PAGE and transferred
to polyvinylidene ﬂuoride membranes. Membranes were blocked
with 5% nonfat dried milk in TBST (15mM Tris–HCl, pH 7.4, 0.9%
NaCl, and 0.05% Tween-20, pH 7.4) followed by blot analysis with
the following speciﬁed antibodies: rabbit monoclonal anti-human
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Fig. 1. Representative IHC staining patterns of TR4 positive and TR4 negative cells in paired specimens. (A) Left: NSCLC tissue with positive TR4 expression. Right: Matched
adjacent normal tissue with negative TR4 expression. (B) The levels of TR4 in 35 NSCLC specimens were signiﬁcantly higher than matched adjacent normal tissues. (C)
Representative IHC staining of TR4 positive and TR4 negative cells. Left: NSCLC with the expression of TR4 interpreted as negative. Right: NSCLC with the expression of TR4

















Xnd F) Kaplan–Meier survival curves demonstrated that high levels of TR4 were ass
egend, the reader is referred to the web version of this article.)
R4 antibody (1:1000 dilution; Abcam, UK); rabbit polyclonal
nti-human Twist antibody (1:400 dilution; Abcam, UK); rabbit
olyclonal anti-human Snail antibody (1:1000 dilution; Abcam,
K); rabbit monoclonal anti-human Vimentin (1:1000 dilution;
ell Signaling Technology, USA); rabbit monoclonal anti-human E-
adherin (1:1000 dilution; Cell Signaling Technology, USA); rabbit
nti-GAPDH (1:10,000 dilution; Cell Signaling Technology, USA)
nd goat anti-rabbit secondary antibody (1:2000). Signals were
isualized by using chemiluminescence (Millipore).
.8. Immunoﬂuorescence staining
Stable transfected cells were cultured in 60mm culture plates
nd trypsinized then plated in chamber slides (Millicell EZ Slide:
illipore, EMD Millipore Corporation, Billerica, MA, USA). Cells
ere then ﬁxed with 4.0% paraformaldehyde in phosphate-
uffered saline for 30min and then permeabilized with 0.2% Triton
-100 for 15minat roomtemperature. After rinsing twicewithPBS,d with poor OS and DFS. (For interpretation of the references to color in this ﬁgure
cellswere incubated for 1–2hwith anti-vimentin (1:200) or anti-E-
cadherin (1:200). Cells were then washed with PBS and incubated
with secondary antibody (Rhodamine TRITC-Conjugated Afﬁnity
Pure Goat Anti-Rabbit IgG, ZSBIO, Beijing) for 45min. Nuclei were
counterstained with 4,6-diamidino-2-phenylindole (1:1000) for
10min at room temperature followed by three washes (5–10min
each). The cells were thenmounted with polymount antifade solu-
tion (Sigma) and observed under a TCS-SP5 confocal laser scanning
microscope (LEICA, Germany).
2.9. Statistical analysis
The immunohistochemical expression and clinicopathologic
datawere summarizedusing standard frequency tabulations. Asso-
ciations between the markers expression and patients’ clinical
variables were assessed using the 2 test and the Fisher exact test.
The Spearman rank r was used to estimate the correlation between
immunohistochemicalmarkers. Survival rateswereestimatedwith
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Fig. 2. (A) TR4 expression in lung cancer cell lines. (B) Knock-down of TR4was evaluated by QPCR andWestern blotting in PC-9 and A549 cells. (C) Overexpression of TR4was
veriﬁed by QPCR and Western blotting in GLC82 and H1299 cells. (D–G) Effects of TR4 on NSCLC cell migration and invasion, and effects of TR4 on NSCLC cell proliferation.
(D) Transwell assays were used to investigate the changes in migratory and invasive abilities of shTR4-transfected PC-9 and A549 cells. (E) Transwell assays were used to
investigate the changes in migratory and invasive abilities of TR4-overexpressing GLC82 and H1299 cells. (F) Colony-formation assays were conducted to determine the
proliferation of shTR4-transfected A549 cells. (G) Colony-formation assays were conducted to determine the proliferation of shTR4-transfected PC-9 cells. (H) Analysis of
E-cadherin, N-cadherin, Vimentin, Snail-1 and Twist expression in A549 cells treated with shTR4 by QPCR. (I) Analysis of E-cadherin, Vimentin, Snail-1 and Twist expression
in A549 cells treated with shTR4 by western blot. All experiments were performed in triplicate independently. (J) Analysis of E-cadherin, N-cadherin, and Vimentin mRNA
expression in TR4-overexpressing H1299 cells by QPCR. (K) Analysis of E-cadherin, Vimentin and N-cadherin expression in TR4-overexpressing H1299 cells by western blot.
All experiments were performed in triplicate independently.
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Table 1
Correlationbetween theclinicopathological featuresandexpressionofTR4 (n=291).
Variables No. of patients % TR4 expression P-value
Negative Positive
Age (years) 0.801
≤60 120 (41.2) 90 30
>60 171 (58.8) 126 45
Gender 0.410
Male 167 (57.4) 127 40
Female 124 (42.6) 89 35
Histology 0.997
Squamous cell carcinoma 117 (39.5) 85 30
Adenocarcinoma 152 (52.2) 113 39
Others 23 (7.9) 17 6
Unknown 1(0.3) 1 0
Histologic grading 0.102
Well 17 (5.8) 11 6
Moderate 145 (49.8) 115 30
Poorly 122 (42.0) 84 38
Unknown 7(2.4) 6 1
TNM stage 0.003*
I, II 193 (66.4) 154 39
IIIA 98 (33.7) 62 36
Tumor stage 0.163
T1 and T2 197 (67.7) 151 46
T3 and 95 (32.0) 65 30
Unknown 1(0.3) 0 1
Lymph node metastasis <0.0001*
Yes 134 (51.5) 84 50
No 150 (46.0) 125 25
Unknown 7(2.4) 7 0
Tumor thrombus in vena 0.025*
No 244 (83.8) 187 57


























FUnknown 1(0.3) 1 0
* Values with statistical signiﬁcance (P<0.05) were indicated.
he use of the Kaplan–Meier method. The prognostic value of TR4
as studied with the use of a Cox model, which was adjusted for
ge, gender, stageandhistology.P<0.05wasconsidered signiﬁcant.
ll statistical analyses were performed using SPSS 17.0 statistical
oftware.
. Results
.1. TR4 expression is upregulated in NSCLC
To determine the clinical relevance of TR4, we ﬁrst detected
his protein expression level in 35 paired NSCLC tumor and nor-
al tissues by IHC. The IHC data revealed that TR4 was strongly
xpressed in tumor tissues compared with normal counterpart tis-
ues (Fig. 1A). In addition, our results showed that the TR4 positive
requencywas signiﬁcantly higher in tumor tissues comparedwith
ormal counterpart tissues (Fig. 1B, P<0.05).
.2. A high level of TR4 expression is associated with poor
rognosis in NSCLC patients
Next, we investigated TR4 expression in 291 clinical NSCLC
pecimens with clinicopathological characteristics shown in
ppendices A and B Table A1. According to IHC staining of TR4,
eak/negative staining for TR4 expression was considered to
xhibit negative expression and the tumor samples with higher
taining were scored as positive expression (Fig. 1C). As shown in
able 1, therewasno signiﬁcant correlationbetweenTR4 levels and
ender, age at surgery, tumor status (T), degree of cell differentia-
ion or histological subtype. Importantly, the expression of TR4 in
he NSCLC tissues with lymph node metastases was signiﬁcantly
igher than tissues without lymph node metastases (P<0.0001;
ig. 1D). Additionally, the expression of TR4 increased remark-r 89 (2015) 320–328
ably in advanced NSCLC TNM stages (P=0.003) and tumor venous
thrombus (P=0.025).
Weexaminedwhether variables of TR4expression couldpredict
overall survival (OS) and disease-free survival (DFS) in the cohort
of patients. Compared to the TR4-negative expression group, the
patients with TR4 positive staining showed signiﬁcantly shorter
OS (69 months versus 35 months; P=0.006) and DFS (53 months
versus 21 months; P=0.005) by Kaplan–Meier analyses (Fig. 1F).
These results suggest that the increased expression of TR4mayplay
an important role in the development and progression of NSCLC.
Furthermore, a Cox proportional hazards model was applied
to estimate the effect of TR4 expression on OS and DFS. The
results showed that TR4 remained signiﬁcantly associatedwithDFS
(Table 2, P=0.022), and exhibited a borderline signiﬁcance in OS
(Table 2, P=0.057). The crude hazard ratio (HR) of TR4 positive
expression compared with TR4 negative expression was 1.407 of
OS (95% CI, 0.989–2.001) and 1.478 of DFS (95% CI, 1.057–2.067),
respectively. Taken together, our data predicted that the expres-
sion of TR4 demonstrated a signiﬁcantly worse prognosis in NSCLC
patients. Table 2 further showed the results of the univariate and
multivariate analyses.
3.3. TR4 induced cell migratory and invasive ability in NSCLC cell
lines
Our data mentioned above suggests that the increased expres-
sion of TR4 in NSCLC specimens correlated with lymph node
metastasis and poor outcome in NSCLC patients. Previously, it
has been reported that TR4 promoted prostate cancer cell migra-
tion/invasion in vitro and in vivo mice studies [28]. Therefore, we
further evaluated the roles of TR4 in themetastatic ability of NSCLC
cell lines. First, expression of TR4 was detected in lung cancer cell
lines (A549, H1299, GLC82 and PC-9) by Western blotting. TR4
mRNA and protein were highly expressed in A549 and PC-9 cell
lines (Fig. 2A). The knockdown assay was performed in A549 and
PC-9 cells transfected by the knockdown agent of GPH1/GFP/Neo-
shTR4 (named as shTR4) and the pGPH1/GFP/Neo-shNC was used
as control (named as control). H1299 and GLC82 cells that lack
endogenous TR4 expression were used in this study to establish
two stable cell lines that constitutively overexpress the TR4 pro-
tein via transfected by the GV144 vector (named as TR4) and the
control vector (named as control). The transfection efﬁciency was
veriﬁed by using QPCR and Western blotting (Fig. 2B and C). Next,
we used the Transwell migration and invasion assays to assess the
effects of TR4 on the migration and invasion in both TR4 gain-of-
function and loss-of-function cell lines. As shown in Fig. 2D, stable
TR4 knockdown resulted in a 44.87% reduction in migration rates
(P=0.0185) and a 45.15% reduction in invasion rates (P=0.0037)
comparedwith the control cells. In contrast, overexpression of TR4
augmented the migratory and invasive capabilities of H1299 and
GLC82 cells. TR4 overexpression in H1299 cells resulted in a 60.60%
increase in migration rates (P=0.0035) and a 68.75% increase in
invasion rates (P=0.05) compared with the control cells (Fig. 2E).
These results were consistent with clinical sample analyses, indi-
cating that TR4was associatedwithmetastatic potentials of NSCLC
cells.
3.4. TR4 enhanced colony formation ability in NSCLC cell lines
We further examined whether TR4 inﬂuenced the proliferation
abilityofNSCLCcells. TheA549-shTR4cells and theA549-shNCcells
were seeded in plates for colony formation analysis. Knockdown of
TR4 signiﬁcantly diminished the colony formation rates of A549
cells compared with the control group (P=0.0002) (Fig. 2F). We
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Table 2
Univariate and multivariate Cox regression analyses for disease free survival (DFS) or overall survival (OS) of patients (n=291).
DFS OS
Variables HR(95%CI) P value HR(95%CI) P value
Univariate analysis
Age (>60 vs. 60 years) 0.812(0.590–1.116) 0.199 1.208(0.879–1.661) 0.243
Gender (male vs. female) 0.900(0.657–1.233) 0.511 0.808(0.591–1.106) 0.183
Histological classiﬁcation (Squamous cell carcinoma vs. Adenocarcinoma/Others) 1.066(0.768–1.478) 0.703 1.050(0.811–1.359) 0.7102
TNM stage (I vs. II/IIIA) 1.829(1.224–2.732) 0.000 1.403(1.192–1.653) 0.000
Tumor stage (T1 vs. T2/T3) 1.274(0.820–1.980) 0.281 1.228(1.002–1.504) 0.047
Lymph node metastasis (negative vs. positive) 2.171(1.581–2.982) 0.000 2.034(1.481–2.793) 0.000
Tumorthrombus in vana (negative vs. positive) 1.365(0.902–2.067) 0.141 1.379(0.916–2.076) 0.124
Histologic grading (well vs. moderate/poorly) 1.517(1.154–1.995) 0.003 1.544(1.171–2.035) 0.002
TR4 expression (negative vs. positive) 1.631(1.159–2.296) 0.005 1.616(1.151–2.269) 0.006
Multivariate analysis
Age (>60 vs. 60years) NA NA
Gender (male vs. female) NA NA
Histological classiﬁcation (Squamous cell carcinoma vs. Adenocarcinoma/others) NA NA
TNM stage (I vs. II/IIIA) 1.610(1.311–1.977) 0.000 1.486(1.225–1.804) 0.000
Tumor stage (T1 vs. T2/T3) 0.821(0.655–1.031) 0.089 NA





































sTumorthrombus in vana (negative vs. positive)
Histologic grading (well vs. moderate/poorly)
TR4 expression (negative vs. positive)
lso observed that TR4 knockdown induced colony formation rates
ecreased in PC-9 cells (P=0.0029) (Fig. 2G).
.5. Down-regulation of TR4 suppressed the EMT phenotype
To further explore mechanisms associated with increased
etastasis potential, we tested essential EMT-related factors,
ncluding E-cadherin, Vimentin, Twist and Snail by conducting
PCR and Western blotting assays in the cells. We found that
549-shTR4 cells expressed lower mRNA levels of mesenchymal
arkers, suchasVimentin (P=0.0001), Snail (P=0.025),N-cadherin
P=0.026), and Twist, whereas higher mRNA levels of the epithe-
ial marker of E-cadherin were observed. In addition, we observed
ncreased expression of the epithelial marker E-cadherin and
ecreased expression of mesenchymal markers Vimentin, Twist
nd Snail in A549-shTR4 cells by immunoblotting (Fig. 2H and I).
e then examined both epithelial and mesenchymal markers in
R4-expressing H1299 cells. As can be seen in Fig. 2J and K, TR4-
xpressing H1299 cells exhibited a signiﬁcant loss of E-cadherin
P=0.026), meanwhile the mesenchymal markers Vimentin, N-
adherinwere upregulated. However, the expression of twoknown
MT inducers, Twist and Snail, were not detectable in H1299 and
LC82 cells. QPCR and Western blotting assays were conﬁrmed
y confocal microscopy (Fig. 3A–D). We found that a signiﬁcant
ncrease of E-cadherin was concurrent with a loss of Vimentin
xpression in A549-shTR4 cells. Similar results were obtained by
mmunoﬂuorescence in PC-9-shTR4 cells. Together, these observa-
ions show that induction of metastasis might be through the EMT
henotype in NSCLC cells.
.6. Relationship between TR4 and EMT markers in NSCLC
We used immunohistochemical methods to analyze the fre-
uency of two EMT-related markers (Vimentin and E-cadherin)
n an investigation cohort, including 30 TR4-positive tumors and
0 TR4-negative tumors. Representative microphotographs of the
xpression of these two biomarkers are shown in Fig. 3E–H. As
he presence of Vimentin in tumor cells rather than its inten-
ity is examined as a marker of EMT, the percentage of Vimentin
n TR4-positive tumors and TR4-negative tumors was 20% (6/30)
nd 0 (0/30), respectively. The loss of E-cadherin expression has
reviously been implicated in the progression and metastasis of
everal malignancies. In this cohort, the percentage of E-cadherinNA NA
1.259(0.972–1.631) 0.081 1.365(1.030–1.809) 0.030
1.478(1.057–2.067) 0.022 1.407(0.989–2.001) 0.057
in TR4-positive tumors and TR4-negative tumors was 20% (6/30)
and33.3% (10/30), respectively. Subsequently,weanalyzed the cor-
relations between TR4, Vimentin and E-cadherin expression levels
and showed that TR4 expression had positive correlations with the
expression of Vimentin (r=0.336, P=0.009). However, no correla-
tionwas foundbetweenTR4 andE-cadherin expression (r=−0.151,
P=0.243).
4. Discussion
It has been established that TR4plays a critical role in embryonic
development, lipidmetabolism [29] and theprogressionofprostate
cancer aswell aspituitary corticotroph tumordevelopment [16,22].
A number of studies have clearly shown that TR4 is aberrantly
expressed in many types of human cancer, such as HepG2 cells
of hepatocellular carcinoma, prostate cancer and pituitary cor-
ticotroph tumors [16,21,22]. However, little is known about its
expression and signiﬁcance in NSCLC. Thus, we have explored this
research to better understand the effects of TR4 in NSCLC.
In our present study, we revealed that TR4 is strongly expressed
in NSCLC specimens with 42.9% positive frequency in tumor tis-
sues and 20% in corresponding normal tissues. Furthermore, we
explored TR4 expression in 291 cases of NSCLC and high level of
TR4 expression was signiﬁcantly associated with poor DFS and
OS. All those results strongly suggested that TR4 overexpression
might represent a biologically and clinically distinct type of cancer
exhibiting highly-malignant clinical behavior.
It is well known that lung cancer is a disease of uncontrolled
cell growth in lung tissues that may lead to metastasis, including
invasion of neighboring tissues and inﬁltration beyond the primary
tumor. We observed that high expression of TR4 was related to
lymph node metastasis in NSCLC, indicating TR4 could be used as
an independent prognostic and metastatic factor for NSCLC. Next,
we investigated the mechanism of metastasis mediated by TR4.
As expected, the inhibition or over-expression of TR4 was shown
to successfully reduce or promote the proliferation, migration and
invasion of NSCLC cells, similar to its function in prostate cancer
[37]. EMT has been implicated to be a potential marker of invasion
and metastasis in lung cancer [30,31]. We assessed these various
EMT-related markers in TR4-inhibited or over-expressed lung
cancer cells and observed down-regulation of Snail, Twist,
Vimentin and N-cadherin expressions [25] and up-regulation of E-
cadherin, CK19andEpCAMin the lungcancer cellswithknockdown
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Fig. 3. (A–D) Fluorescence staining for E-cadherin and Vimentin in A549 cells. Representative confocal pictures are shown. Rhodamine TRITC-red is used for E-cadherin and
Vimentin, whereas DAPI-blue stains the nuclei. (E–H) Representative IHC staining for Vimentin and E-cadherin. (E) NSCLC with the expression of E-cadherin interpreted
a (G) NS




Vs positive. (F) NSCLC with the expression of E-cadherin interpreted as negative.
xpression of vimentin interpreted as negative. (For interpretation of the referencef TR4 compared with the control cells and opposite manner in
hose with over-expressed TR4. But the limited number of spec-
mens used to explore the relationship of TR4 and E-cadherin,
imentin by IHC makes it difﬁcult to get a clear conclusion.CLC with the expression of vimentin interpreted as positive. (H) NSCLC with the
lor in this ﬁgure legend, the reader is referred to the web version of this article.)There are still many details to be explored regarding the mech-
anisms of TR4 in NSCLC. TR4 has been reported to belong to the
estrogen receptor (ER)/thyroid hormone receptor subfamily that
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ecently reported that ER1 is an independent positive progno-
tic factor for survival in early-stage NSCLC patients as well as in
etastatic NSCLC [34,35]. Subsequently, the interaction between
R4 and ER is required for further study.
TR4 has been found to be involved in fundamental biological
rocess, such as RNA metabolism, protein translation, ubiquitin
ycle, metabolic processes, lipid recruitment and gluconeogene-
is [9,29]. It has previously been proven that TR4 can regulate
everal signal pathways in cancer cells of liver, skin and prostate
16,22,29,38]. The studies from TR4 gene knock-outmice (TR4−/−)
rovide valuable clue to intensive research on TR4 [10,11,36–38].
hese results indicate TR4 might not only affect the metastasis
f lung cancer, but also play some role in drug resistance and
etabolism.
In conclusion, the present study showed that TR4 is frequently
pregulated in NSCLCs, leading to poor prognosis, an increase in
ymph node metastasis and advanced NSCLC TNM stages. Our data
urtherdemonstrated that TR4 could inducemigratory and invasive
roperties in NSCLC cells, and that down-regulation of TR4 could
educe the EMT phenotype. The evidence may lead to the applica-
ion of TR4 in the development of new diagnostic and therapeutic
pproaches for the treatment of NSCLC.
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